Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Parallel Design, Double-blind, Randomised, Placebo-controlled, Multi-centre Trial to Evaluate the Efficacy and Safety of Nerandomilast Oral Therapy Added to Standard Background Therapy Over 52 Weeks in Adult Trial Participants With Active Idiopathic Inflammatory Myopathies (VERANDA™-IIM)

NCT07789015 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT07789015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07789015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Parallel Design, Double-blind, Randomised, Placebo-controlled, Multi-centre Trial to Evaluate the Efficacy and Safety of Nerandomilast Oral Therapy Added to Standard Background Therapy Over 52 Weeks in Adult Trial Participants With Active Idiopathic Inflammatory Myopathies (VERANDA™-IIM)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Not yet recruiting
Start date
December 14, 2026
Completion date
April 4, 2030
Enrollment
270 (estimated)
Sites
150

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic inflammatory myopathies